Movac Emerge Fund 4 has reached first close at >$30m and is currently open for investment.

$30-50mFund size 




Emerge 4 Fund

Emerge Fund 4 will invest in high-growth tech companies raising pre-Seed to Series A.

Our experience with companies like PowerbyProxi and Aroa Biosurgery has demonstrated that maximum returns can be achieved by being involved early and participating through multiple rounds with increasingly larger investments. This is a strategy we followed from Fund 1 to Fund 3, and continued to follow while deploying Fund 5, and will continue with Emerge Fund 4.

Offers exposure to:

Emerging, early-stage New Zealand technology companies
A well diversified portfolio of 10-15 investments

We look for:

Founders with pioneering product visions
Clear pathway to commercialisation
Targeting large, global markets
A defensible moat

We need:

Pre-revenue or early commercialisation (up to ~$2m in revenue)
Opportunity to follow-on in later rounds
New Zealand nexus or connection

The minimum investment is NZ$50,000, spread over the first 2-3 years.
Note that you need to be a Wholesale Investor, as defined by the Financial Markets Conduct Act 2013.


If you would like to learn more about investing in Emerge Fund 4, contact Movac Partner Mark Vivian.

Movac is New Zealand’s most experienced technology investor.

We have been building iconic Kiwi companies for more than 20 years and have been a trusted partner for over 50 companies and their founders across 5 funds.

With more than $500m in funds raised, we have earned the trust of some of NZ’s largest institutions, iwi, community trusts, and individual investors over a number of funds. Every Movac Fund has been in the top quartile, or top decile, internationally for funds returned to investors. The New Zealand technology sector has matured and proven its ability to produce internationally competitive companies of value and scale. We believe there is currently a distinct opportunity to deliver outsize returns in the NZ market and our investors will be best served by a specific early stage ‘Emerge’ fund. Contact Mark Vivian to find out more.